About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as "Meiji Seika Pharma") today announced its investment in ARCALIS, Inc. (Headquarters: Minami-soma City, Fukushima Prefecture; President: Satoshi Takamatsu; hereinafter referred to as "ARCALIS").

ARCALIS is a joint venture between Axcelead, Inc., which manages a group of world-class pharmaceutical and healthcare platform companies, and Arcturus Therapeutics, Inc. a commercial mRNA medicines and vaccines company. ARCALIS is engaged in the development of mRNA pharmaceuticals and vaccines, as well as contract development and manufacturing organization (CDMO) services. The company plans to establish a comprehensive system for the domestic production of mRNA vaccines, ranging from the development of manufacturing technologies to the production of both active pharmaceutical ingredients and formulations.

In response to the lessons learned from the delays experienced in the development of COVID-19 vaccines during the pandemic, ARCALIS and Meiji Seika Pharma are committed to advancing the development, production, and supply of mRNA vaccines in line with the "Strategy for Strengthening Vaccine Development and Production Systems" adopted by the Japanese government. This strategy is designed to ensure that the necessary quantities of vaccines are delivered to the population in a timely manner when they are needed.

This investment will further strengthen the collaborative relationship between the two companies. The combination of ARCALIS' advanced technology and operations in mRNA pharmaceuticals and vaccines with Meiji Seika Pharma's expertise in manufacturing, post-marketing safety management and stable product supply is expected to significantly improve the supply of mRNA vaccines in Japan.

Meiji Seika Pharma plans to supply the domestically produced next-generation sa-mRNA vaccine (replicon) ‘KOSTAIVE® for Intramuscular Injection’ in December 2024. This vaccine will be formulated by a Meiji Seika Pharma Group company using the active pharmaceutical ingredient produced by ARCALIS. Supply will commence upon approval of the partial change in manufacturing and marketing authorization for the additional domestic manufacturing sites currently under application.

Meiji Seika Pharma is committed to the timely and reliable production and supply of essential vaccines to the public in response to potential future infectious diseases.

About Meiji Seika Pharma

Meiji Seika Pharma, since it launched penicillin in 1946, has been providing efficacious and high-quality pharmaceutical products including therapeutics and vaccines for infectious diseases, therapeutics for central nervous system diseases and generic drugs, to meet various medical needs.(https://www.meiji.com/global/pharmaceuticals/

About ARCALIS

ARCALIS is an mRNA vaccines and therapeutics contract development and manufacturing organization (“CDMO”), jointly established by Axcelead, Inc. and Arcturus Therapeutics, Inc.. ARCALIS aims to develop the world’s first mRNA vaccines and therapeutics CDMO business that promises a stable supply of high-quality mRNA medicines to all customers, including Arcturus, other pharmaceutical companies, biotech companies, and academic institutes worldwide. (https://corp.arcalis.co.jp/en/)

About Axcelead

Axcelead is a healthcare platform company that owns Axcelead Drug Discovery Partners, Inc., Japan’s first drug discovery solution provider, and ARCALIS Inc., a CDMO company capable of integrated manufacturing of mRNA pharmaceuticals. (https://www.axcelead-hd.com/en-home/)

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc. founded in 2013, is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. (https://arcturusrx.com/)

Contacts

Meiji Seika Pharma

Public Relations

Sayoko Taga

pr-pharma@meiji.com

Axcelead, Inc. & ARCALIS, Inc.

Public Relations & Investor Relations

Mitsuo Oguri

mitsuo.oguri@axcelead.com

Arcturus Therapeutics

Public Relations & Investor Relations

Neda Safarzadeh

VP, Head of IR/PR/Marketing

(858) 900-2682

IR@ArcturusRx.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.